Clinical trials have shown that the majority of the weight loss typically occurs within the first 16-20 weeks of treatment, with continued gradual weight loss over the following months
Diabetologia 66(10):18691881 Chuang MH, Chen JY, Wang HY, Jiang ZH, Wu VC (2024) Clinical outcomes of Tirzepatide or GLP-1 receptor agonists in individuals with type 2 diabetes
may only help in people who are deficient [16] Chromium: promoted for cravings and glucose regulation, evidence is mixed [17] Resveratrol: added for longevity benefits
Companies like JING YOUNG BIOTECH BUSINESS CO., LTD
These include specific kidney conditions such as distal renal tubular acidosis and medullary sponge kidney, gout, hyperparathyroidism, inflammatory bowel disease (particularly Crohn's disease), and recurrent urinary tract infections